If approved, it will be the Thousand Oaks-based biotech giant’s first new drug on the market since the FDA’s landmark approval of the first-ever biosimilar drug on the American market.
With California in the midst of some of its driest months on record, the statewide drought is far from over, and one Westlake Village firm is looking to bring farmers some solutions.
On March 9, a company memo announced its plans to shutter San Francisco facilities once belonging to Onyx Pharmaceuticals and lay off 300 employees there.
In a company memo circulated yesterday, Amgen CEO Robert Bradway said the firm will begin reconsolidating oncology operations into its Thousand Oaks headquarters.
